EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Madame Bioscience Public Company Limited (MADAME) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Madame Bioscience Public Company Limited THB 0.82, price THB 1.04, upside -21.5%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Consumer Defensive · TH

MB Thin data Sep 24, 2026

Madame Bioscience Public Company Limited

MADAME · BK

Weak valuationQuality is weak on top of the rich price.

!Fair value 0.8160 THB · Overvalued (−22%)
!Quality 40/100
!Weak Growth (revenue 3y −12.8 %/yr)
!Loss over the last twelve months · -10.5% net margin (TTM) · fiscal year 2025 3.1%
!Low debt · negative free cash flow
!Trails peers (3/10)
!Narrow moat 21/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 5 out of 100
Watch Madame Bioscience Public Company Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

6.60 THB 0.4300 THB Fair Value 0.8160 THB Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 0.4300 THB – 6.60 THB · fair‑value band 0.6120 THB – 1.02 THB · the 1.04 THB price screens above the 0.8160 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Madame Bioscience Public Company in your weekly email

Every Wednesday you see whether Madame Bioscience Public Company is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Madame Bioscience Public Company Limited, together with its subsidiaries, engages in the food business in Thailand. It operates through Packaging Business, Retail Sales of Cosmetics, Food Business, and Other Business segments.

Show more

Madame Bioscience Public Company Limited, together with its subsidiaries, engages in the food business in Thailand. It operates through Packaging Business, Retail Sales of Cosmetics, Food Business, and Other Business segments. The company offers various food products, including frozen processed and ready-to-eat food, chilled food, plant-based food, hemp food, processed food, and sauces under the Kitchen Plus and Look Chin Tip brands. It also provides flexible packaging, polyethylene terephthalate bottles, and food packaging trays for packaged food and beverages. In addition, the company engages in the manufacture and sale of plastic packaging, seafood, and processed meat; retail sale of cosmetics; advertising rental services in gas stations; restaurant business; network marketing; and trading activities. The company was formerly known as Global Consumer Public Company Limited and changed its name to Madame Bioscience Public Company Limited in July 2025. Madame Bioscience Public Company Limited was founded in 1987 and is headquartered in Bangkok, Thailand.

Stock analysis

Madame Bioscience Public Company Limited (MADAME) currently trades at 1.04 THB, while our model-based Fair Value estimate is 0.8160 THB, implying the stock looks roughly 27.5% overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of 1.98 THB per share, and 2 of the 8 models we run sit above the 1.04 THB price.

Bear case: the Earnings-Based group reads lowest at 0.4700 THB, and 6 of the 8 models stay below the price. Evidence for this calculation is low.

Scenario range: 0.6120 THB (bear) to 1.02 THB (bull), the price of 1.04 THB sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Consumer Defensive sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Madame Bioscience Public Company Limited reported revenue of 1.5B THB in FY2025 versus 1.9B THB in FY2021, a compound −5.6%/yr. Reported net income was 45.8M THB in FY2025.

Key figures

Market cap 840M THB (≈ $25.1M) · P/S ratio 0.34 · EPS (TTM) −0.2000 THB · Net margin 3.1% · Return on equity −20.4% · Return on assets (EBIT) −9.5% · Operating margin 6.4% · Revenue (TTM) 1.5B THB.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).

What moves the price

The share trades about 9% below its 52-week high and 142% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at −3% fair-value upside, at −22%, MADAME screens richer than that median.

Fair Value models

Bear 0.6120 THB Fair Value 0.8160 THB Bull 1.02 THB
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings 1.46 THB 1.98 THB 2.92 THB 73
Residual Income 0.7200 THB 0.7400 THB 0.7400 THB 73
Graham-Dodd 0.3900 THB 0.4700 THB 0.5300 THB 65
All 8 models by family
DCF Models
Owner Earnings 1.46 THB 1.98 THB 2.92 THB 73
Earnings-Based
Graham-Dodd 0.3900 THB 0.4700 THB 0.5300 THB 65
Multiples
P/E Multiple 0.9300 THB 1.25 THB 1.56 THB 63
P/S Multiple 0.7200 THB 0.9600 THB 1.20 THB 58
P/B Multiple 0.7200 THB 0.9600 THB 1.20 THB 55
Asset-Based
NCAV (Graham) 0.4600 THB 0.6200 THB 0.9300 THB 54
Economic Profit
Residual Income 0.7200 THB 0.7400 THB 0.7400 THB 73
Growth Earnings
Growth-Adj P/E 0.6600 THB 0.9400 THB 1.22 THB 65

Open the full fair value analysis →

Notify me when MADAME reaches fair value

Put MADAME on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 40/100

Of which business quality 41 · Market factors (momentum, volatility) 67

Profitability 44
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 16
Earnings quality: real cash, not paper profit
Fin. Strength 53
Balance sheet, leverage, solvency risk
Investment 98
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 81
Price trend over the last 3–12 months (market factor)
52W Momentum 62
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 14/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−30.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6.2% (2021) → −14.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

MADAME screens 27% overvalued. Compare with Nestlé S.A →

Compare Madame Bioscience Public Company Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 668 stocks

Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 40 · Bottom 25%
Fair Value upside −22% · Below median
Profitability
Return on assets −17% · Bottom 25%
Net margin (TTM) −11% · Bottom 25%
Operating margin (TTM) 6% · Above median
Growth and dividend
Revenue growth 15% · Top 25%
Balance sheet
Debt / equity 0.19× · Above median

Valuation Multiplesvs Packaged Foods median · lower = cheaper

P/S (TTM) 0.02× · Cheapest 25%
PEG 2.50× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)5 · sector 31
FUTURE (revenue growth)77 · sector 20
PAST (return on equity)0 · sector 29
HEALTH (low debt)91 · sector 96
DIVIDEND (yield)0 · sector 58

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Packaged Foods stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Nestlé S.A NESN CHF 77.94 CHF 59.51 −24%
Danone S.A BN €60.14 €50.81 −16%
The Kraft Heinz Company KHC $23.79 $29.20 +23%
Foshan Haitian Flavouring and Food Company 603288 ¥34.29 ¥37.72 +10%
Nestlé India Limited NESTLEIND ₹1,387 ₹724.74 −48%
Inner Mongolia Yili Industrial Group 600887 ¥26.77 ¥41.84 +56%
Yihai Kerry Arawana Holdings 300999 ¥25.12 ¥9.98 −60%
General Mills, Inc GIS $35.82 $34.66 −3%
Uni-President Enterprises Corp 1216 74.50 TWD 68.72 TWD −8%
McCormick & Company MKC $49.09 $51.01 +4%

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Madame Bioscience Public Company Limited · Fair Value
0.8160 THB −27%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Madame Bioscience Public Company Limited Fair Value". https://www.fairvalue-calculator.com/stock/MADAME

Frequently asked questions

Is Madame Bioscience Public Company Limited (MADAME) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 0.8160 THB versus a price of 1.04 THB, about −22% upside (overvalued).
What is the fair value of MADAME?
Our model-based fair value for Madame Bioscience Public Company Limited is 0.8160 THB (as of Sep 24, 2026), built from audited fundamentals. The current price: 1.04 THB.
What is the quality score of MADAME?
Madame Bioscience Public Company Limited has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Madame Bioscience Public Company Limited (MADAME)?
Our model-based price target is the fair value of 0.8160 THB (as of Sep 24, 2026) from 8 valuation models. Cautious scenario 0.6120 THB, optimistic scenario 1.02 THB. It is a calculation from audited fundamentals, not an analyst target.
What is the Madame Bioscience Public Company Limited stock forecast for 2026?
Our models put fair value at 0.8160 THB, about −22% upside versus a price of 1.04 THB (overvalued). Cautious scenario 0.6120 THB, optimistic scenario 1.02 THB. The calculation is refreshed regularly with new filings.
What is the revenue of Madame Bioscience Public Company Limited (MADAME)?
Madame Bioscience Public Company Limited reported trailing-twelve-month revenue of about 1.5B THB (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Madame Bioscience Public Company Limited (MADAME)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Madame Bioscience Public Company Limited it is 0.8160 THB per share (as of Sep 24, 2026), against a price of 1.04 THB. It is the blended result of 8 valuation models (cash flow, earnings, asset, dividend).
Is Madame Bioscience Public Company Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, MADAME trades above its calculated fair value: price 1.04 THB, fair value 0.8160 THB, a gap of about −22% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MADAME?
No. The price is what the market pays today (1.04 THB); the fair value is what the company's own numbers justify (0.8160 THB). For Madame Bioscience Public Company Limited the two are 0.2240 THB per share apart. That gap is exactly why we show both numbers side by side.
How much is Madame Bioscience Public Company Limited worth?
The market values Madame Bioscience Public Company Limited at about 840M THB (market capitalisation, as of Sep 24, 2026). Per share that is 1.04 THB; our models calculate a fair value of 0.8160 THB per share.
What do the bullish and bearish scenarios say about MADAME?
Our models span a range for Madame Bioscience Public Company Limited: cautious scenario 0.6120 THB, base 0.8160 THB, optimistic 1.02 THB per share (as of Sep 24, 2026, price 1.04 THB). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of MADAME?
The PEG ratio of Madame Bioscience Public Company Limited is 2.50 (P/E divided by earnings growth, as of Sep 24, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Madame Bioscience Public Company Limited (MADAME)?
Balance-sheet figures for Madame Bioscience Public Company Limited (as of Sep 24, 2026): return on equity −20.4%, debt of 0.19 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is MADAME from its 52-week high?
Madame Bioscience Public Company Limited trades at 1.04 THB, about 9% below its 52-week high of 1.14 THB and 142% above the low of 0.4300 THB (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 0.8160 THB is for.
Which stocks are comparable to Madame Bioscience Public Company Limited?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, The Kraft Heinz Company, Foshan Haitian Flavouring and Food Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Madame Bioscience Public Company Limited stock attractive at the current price?
The data as of Sep 24, 2026: price 1.04 THB, calculated fair value 0.8160 THB (−22%), Quality Score 40/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MADAME calculated?
We run Madame Bioscience Public Company Limited through 8 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.8160 THB, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Madame Bioscience Public Company Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Madame Bioscience Public Company Limited (MADAME)?
The closing price on Sep 24, 2026 was 1.04 THB. Our model-based fair value is 0.8160 THB, about −22% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Madame Bioscience Public Company Limited right now?
Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Madame Bioscience Public Company Limited

How large is the market capitalisation of Madame Bioscience Public Company Limited (MADAME)?
The market capitalisation of Madame Bioscience Public Company Limited is 840M THB (≈ $25.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Madame Bioscience Public Company Limited (MADAME)?
The price-to-sales ratio of Madame Bioscience Public Company Limited is 0.34 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Madame Bioscience Public Company Limited (MADAME)?
Earnings per share at Madame Bioscience Public Company Limited are −0.2000 THB. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Madame Bioscience Public Company Limited (MADAME)?
The net margin of Madame Bioscience Public Company Limited is 3.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Madame Bioscience Public Company Limited (MADAME)?
The return on equity (ROE) of Madame Bioscience Public Company Limited is −20.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Madame Bioscience Public Company Limited (MADAME)?
On an EBIT basis the return on assets of Madame Bioscience Public Company Limited is −9.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Madame Bioscience Public Company Limited (MADAME)?
The operating margin of Madame Bioscience Public Company Limited is 6.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Madame Bioscience Public Company Limited (MADAME)?
Revenue at Madame Bioscience Public Company Limited is growing +15.4% versus a year earlier (3y avg −12.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Madame Bioscience Public Company Limited (MADAME)?
Earnings per share at Madame Bioscience Public Company Limited are growing −90.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Madame Bioscience Public Company Limited (MADAME) generate?
The free cash flow of Madame Bioscience Public Company Limited is −4.6M THB (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Madame Bioscience Public Company Limited (MADAME) carry?
The net debt of Madame Bioscience Public Company Limited is 60.0M THB (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Madame Bioscience Public Company Limited in the live analysis

One click puts Madame Bioscience Public Company Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.